In keeping with its habit of doing things differently, Speedel Holding AG gained a stock market presence without raising any cash, simply by listing all of its issued shares Thursday on the Swiss Stock Exchange in Zurich. (BioWorld International)
In keeping with its habit of doing things differently, Speedel Holding AG gained a stock market presence without raising any cash, simply by listing all of its issued shares Thursday on the Swiss Stock Exchange in Zurich. (BioWorld International)
Algeta ASA raised €23 million (US$28.8 million) in a Series A funding to continue development of its lead product, Alpharadin, a cancer therapeutic based on radium-223 (Ra-223), which is undergoing Phase II studies in skeletal metastases arising from prostate cancer. (BioWorld International)
Algeta ASA raised €23 million (US$28.8 million) in a Series A funding to continue development of its lead product, Alpharadin, a cancer therapeutic based on radium-223 (Ra-223), which is undergoing Phase II studies in skeletal metastases arising from prostate cancer. (BioWorld International)
